In VivoThe US Food and Drug Administration’s complete response letter for Replimune ’s RP1 appears to point the company in a different direction than its previous interactions with the agency, providing fur
ScripWhile the controversy surrounding Sarepta’s Elevidys continues, the future of the Duchenne muscular dystrophy gene therapy on the market looks limited at best – and for patients, their families and in
Pink SheetThe US Food and Drug Administration’s complete response letter for Replimune ’s RP1 appears to point the company in a different direction than its previous interactions with the agency, providing fur
Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan